Physician profile
Robert Usaitis
NPI 1346266889
$7,806.46
in general payments reported to CMS, 2019-2025
40 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $805 · 2021: $1,253 · 2022: $947 · 2023: $988 · 2024: $1,387 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,440 · Education: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,440.02 |
| Education | $406.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,408.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,032.05 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astellas Pharma US INC | $960.21 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $574.94 | 2019-2024 | |
| Lilly USA, LLC | $551.24 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $523.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $379.49 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $318.34 | 2020-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.05 | 2019-2025 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $190.63 | 2019-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $181.80 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $166.27 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Amarin Pharma, INC. | $138.86 | 2020-2021 | |
| Daiichi Sankyo INC. | $110.98 | 2020-2023 | Injectafer |
| Amgen INC. | $103.36 | 2019-2025 | Evenity, Prolia |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Usaitis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.